Copy number variants in pharmacogenetic genes

Trends in Molecular Medicine

Volumn 17, Issue 5, 2011, Pages 244-251

  He, Yijing ^a   Hoskins, Janelle M ^a   McLeod, Howard L ^a  

^a University of North Carolina   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2D6; ESTROGEN RECEPTOR; GLUTATHIONE TRANSFERASE; NORTAMOXIFEN; NORTRIPTYLINE; TAMOXIFEN;

ALLELE; COPY NUMBER VARIATION; DNA POLYMORPHISM; ENZYME ACTIVITY; GASTROINTESTINAL TRACT; GENE DOSAGE; REVIEW;

DNA COPY NUMBER VARIATIONS; GENE DOSAGE; GENE FREQUENCY; HUMANS; PHARMACOGENETICS; POPULATION GROUPS;

EID: 79955671884     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2011.01.007     Document Type: Review

References (95)

1. Meyer U.A. Pharmacogenetics and adverse drug reactions. Lancet 2000, 356:1667-1671.
2. Eichelbaum M., et al. Pharmacogenomics and individualized drug therapy. Annu. Rev. Med. 2006, 57:119-137.
3. de Leon J., et al. The AmpliChip CYP450 genotyping test: integrating a new clinical tool. Mol. Diagn. Ther. 2006, 10:135-151.
4. USFDA (2005) Guidance for Industry: Pharmacogenomic Data Submissions, USFDA.
5. USFDA (2008) Table of Valid Genomic Biomarkers in the Context of Approved Drug Labels, U.S. FDA.
6. Normanno N., et al. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat. Rev. Clin. Oncol. 2009, 6:519-527.
7. Lonjou C., et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008, 18:99-107.
8. Schwarz U.I., et al. Genetic determinants of response to warfarin during initial anticoagulation. N. Engl. J. Med. 2008, 358:999-1008.
9. Roy P.D., et al. Pharmacogenomics of anti-TB drugs-related hepatotoxicity. Pharmacogenomics 2008, 9:311-321.
10. Frueh F.W., et al. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use. Pharmacotherapy 2008, 28:992-998.
11. USFDA (2006) Table of Valid Genomic Biomarkers in the Context of Approved Drug Labels, U.S. FDA.
12. Stamer U.M., et al. Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication. Anesth. Analg. 2008, 107:926-929.
13. Weinshilboum R. Inheritance and drug response. N. Engl. J. Med. 2003, 348:529-537.
14. Redon R., et al. Global variation in copy number in the human genome. Nature 2006, 444:444-454.
15. Schoumans J., et al. Detection of chromosomal imbalances in children with idiopathic mental retardation by array based comparative genomic hybridisation (array-CGH). J. Med. Genet. 2005, 42:699-705.
16. McCarroll S.A., et al. Common deletion polymorphisms in the human genome. Nat. Genet. 2006, 38:86-92.
17. Craddock N., et al. Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature 2010, 464:713-720.
18. Johansson I., Ingelman-Sundberg M. CNVs of human genes and their implication in pharmacogenetics. Cytogenet. Genome Res. 2008, 123:195-204.
19. Zhou S.F. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I. Clin. Pharmacokinet. 2009, 48:689-723.
20. Hoskins J.M., et al. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat. Rev. Cancer 2009, 9:576-586.
21. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2005, 5:6-13.
22. *10 does not increase CYP2D6 metabolic activity. Clin. Chim. Acta 2004, 344:201-204.
23. *36 with poor metabolizer status. Drug Metab. Dispos. 2006, 34:563-569.
24. Steen V.M., et al. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics 1995, 5:215-223.
25. Sistonen J., et al. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet. Genomics 2007, 17:93-101.
26. Fuselli S., et al. Evolution of detoxifying systems: the role of environment and population history in shaping genetic diversity at human CYP2D6 locus. Pharmacogenet. Genomics 2010, 20:485-499.
27. Griese E.U., et al. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population. Pharmacogenetics 1999, 9:715-723.
28. Bradford L.D. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002, 3:229-243.
29. NCBI (2008) Nortriptyline.
30. Yue Q.Y., et al. Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes. Clin. Pharmacol. Ther. 1998, 64:384-390.
31. Dalen P., et al. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin. Pharmacol. Ther. 1998, 63:444-452.
32. Uher R., et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am. J. Psychiatry. 2010, 167:555-564.
33. Wood C.E., et al. Endometrial profile of tamoxifen and low-dose estradiol combination therapy. Clin. Cancer Res. 2010, 16:946-956.
34. Jordan V.C. Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer. Br. J. Pharmacol. 2006, 147(Suppl. 1):S269-S276.
35. Ingle J.N. Pharmacogenomics of tamoxifen and aromatase inhibitors. Cancer 2008, 112:695-699.
36. Desta Z., et al. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J. Pharmacol. Exp. Ther. 2004, 310:1062-1075.
37. Johnson M.D., et al. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res. Treat. 2004, 85:151-159.
38. Borges S., et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin. Pharmacol. Ther. 2006, 80:61-74.
39. Serrano, D. et al.Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial. Pharmacogenomics J.(in press), doi:10.1038/tpj.2010.17.
40. Schroth W., et al. CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification. Clin. Cancer Res. 2010, 16:4468-4477.
41. Prakash A., Markham A. Metoprolol: a review of its use in chronic heart failure. Drugs 2000, 60:647-678.
42. Fux R., et al. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study. Clin. Pharmacol. Ther. 2005, 78:378-387.
43. Kirchheiner J., et al. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther. 2004, 76:302-312.
44. Goryachkina K., et al. CYP2D6 is a major determinant of metoprolol disposition and effects in hospitalized Russian patients treated for acute myocardial infarction. Eur. J. Clin. Pharmacol. 2008, 64:1163-1173.
45. Kirchheiner J., et al. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J. 2007, 7:257-265.
46. Ciszkowski C., et al. Codeine, ultrarapid-metabolism genotype, and postoperative death. N. Engl. J. Med. 2009, 361:827-828.
47. Madadi P., et al. Safety of codeine during breastfeeding: fatal morphine poisoning in the breastfed neonate of a mother prescribed codeine. Can. Fam. Physician 2007, 53:33-35.
48. Madadi P., et al. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin. Pharmacol. Ther. 2009, 85:31-35.
49. Hayes J.D., et al. Glutathione transferases. Annu. Rev. Pharmacol. Toxicol. 2005, 45:51-88.
50. Garte S., et al. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev. 2001, 10:1239-1248.
51. Piacentini, S. et al.GSTT1 and GSTM1 gene polymorphisms in European and African populations. Mol. Biol. Rep.(in press), doi:10.1007/s11033-010-0221-0.
52. Timofeeva M., et al. A multiplex real-time PCR method for detection of GSTM1 and GSTT1 copy numbers. Clin. Biochem. 2009, 42:500-509.
53. Economopoulos K.P., Sergentanis T.N. GSTM1, GSTT1, GSTP1, GSTA1 and colorectal cancer risk: a comprehensive meta-analysis. Eur. J. Cancer 2010, 46:1617-1631.
54. Das P., et al. Meta-analysis study of glutathione-S-transferases (GSTM1, GSTP1, and GSTT1) gene polymorphisms and risk of acute myeloid leukemia. Leuk Lymphoma 2009, 50:1345-1351.
55. Cho H.J., et al. Glutathione-S-transferase genotypes influence the risk of chemotherapy-related toxicities and prognosis in Korean patients with diffuse large B-cell lymphoma. Cancer Genet. Cytogenet 2010, 198:40-46.
56. Farlow M., et al. A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group. J. Am. Med. Assoc. 1992, 268:2523-2529.
57. Kawas C.H. Clinical practice Early Alzheimer's disease. N. Engl. J. Med. 2003, 349:1056-1063.
58. Patocka J., et al. Possible role of hydroxylated metabolites of tacrine in drug toxicity and therapy of Alzheimer's disease. Curr. Drug. Metab. 2008, 9:332-335.
59. Simon T., et al. Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity. Clin. Pharmacol. Ther. 2000, 67:432-437.
60. Fang L., et al. NO-donating tacrine hybrid compounds improve scopolamine-induced cognition impairment and show less hepatotoxicity. J. Med. Chem. 2008, 51:7666-7669.
61. Roederer M.W., McLeod H.L. Applying the genome to national drug formulary policy in the developing world. Pharmacogenomics 2010, 11:633-636.
62. Collins F.S. The Language of Life: DNA and the Revolution in Personalized Medicine 2009, HarperCollins Publisher.
63. Cavaco I., et al. CYP2C8 polymorphism frequencies among malaria patients in Zanzibar. Eur. J. Clin. Pharmacol. 2005, 61:15-18.
64. Stuven T., et al. Rapid detection of CYP2D6 null alleles by long distance- and multiplex-polymerase chain reaction. Pharmacogenetics 1996, 6:417-421.
65. Schaeffeler E., et al. CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR. Hum. Mutat. 2003, 22:476-485.
66. Shinawi M., Cheung S.W. The array CGH and its clinical applications. Drug. Discov. Today 2008, 13:760-770.
67. Pinkel D., et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat. Genet. 1998, 20:207-211.
68. Heller T., et al. AmpliChip CYP450 GeneChip: a new gene chip that allows rapid and accurate CYP2D6 genotyping. Ther. Drug. Monit. 2006, 28:673-677.
69. Rebsamen M.C., et al. The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction. Pharmacogenomics J. 2009, 9:34-41.
70. International HapMap Consortium, The International HapMap Project (2003) Nature 426, 789-796.
71. Deeken J. The Affymetrix DMET platform and pharmacogenetics in drug development. Curr. Opin. Mol. Ther. 2009, 11:260-268.
72. Gaedigk A., et al. Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans. Clin. Pharmacol. Ther. 2002, 72:76-89.
73. Lavender N.A., et al. Examination of polymorphic glutathione S-transferase (GST) genes, tobacco smoking and prostate cancer risk among men of African descent: a case-control study. BMC Cancer 2009, 9:397.
74. Sosa-Macias M., et al. Influence of CYP2D6 deletion, multiplication, -1584C-->G, 31G-->A and 2988G-->a gene polymorphisms on dextromethorphan metabolism among Mexican Tepehuanos and Mestizos. Pharmacology 2010, 86:30-36.
75. Lopez M., et al. CYP2D6 genotype and phenotype determination in a Mexican Mestizo population. Eur. J. Clin. Pharmacol. 2005, 61:749-754.
76. *0 in a Mexican Mestizo population: a similitude analysis. Hum. Biol. 2008, 80:457-465.
77. Aklillu E., et al. Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J. Pharmacol. Exp. Ther. 1996, 278:441-446.
78. Dash B., et al. Determinants of the variability of aflatoxin-albumin adduct levels in Ghanaians. J. Toxicol. Environ. Health A 2007, 70:58-66.
79. Ji L., et al. Genetic polymorphisms of CYP2D6 in Chinese mainland. Chin. Med. J. (Engl.) 2002, 115:1780-1784.
80. Liu L., et al. Genetic polymorphisms of glutathione S-transferase and risk of vitiligo in the Chinese population. J. Invest. Dermatol. 2009, 129:2646-2652.
81. *10. Pharmacogenetics 2000, 10:567-570.
82. Kubota T., et al. Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. Br. J. Clin. Pharmacol. 2000, 50:31-34.
83. Fujihara J., et al. Cytochrome P450 1A1, glutathione S-transferases M1 and T1 polymorphisms in Ovambos and Mongolians. Leg. Med. (Tokyo) 2009, 11(Suppl. 1):S408-S410.
84. Lee S.Y., et al. Sequence-based CYP2D6 genotyping in the Korean population. Ther. Drug Monit. 2006, 28:382-387.
85. Uhm Y.K., et al. Association of glutathione S-transferase gene polymorphisms (GSTM1 and GSTT1) of vitiligo in Korean population. Life Sci. 2007, 81:223-227.
86. Abbas A., et al. GSTM1, GSTT1, GSTP1 and CYP1A1 genetic polymorphisms and susceptibility to esophageal cancer in a French population: different pattern of squamous cell carcinoma and adenocarcinoma. World J. Gastroenterol. 2004, 10:3389-3393.
87. Sachse C., et al. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet. 1997, 60:284-295.
88. McLellan R.A., et al. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics 1997, 7:187-191.
89. Abu-Amero K.K., et al. GSTM1 and GSTT1 deletion genotypes in various spontaneous optic neuropathies in Arabs. Br. J. Ophthalmol. 2009, 93:1101-1104.
90. Rao Y., et al. Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. Mol. Pharmacol. 2000, 58:747-755.
91. Lerman C., et al. Genetic variation in nicotine metabolism predicts the efficacy of extended-duration transdermal nicotine therapy. Clin. Pharmacol. Ther. 2010, 87:553-557.
92. Farinola N., Piller N.B. CYP2A6 polymorphisms: is there a role for pharmacogenomics in preventing coumarin-induced hepatotoxicity in lymphedema patients?. Pharmacogenomics 2007, 8:151-158.
93. Yang P., et al. Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: a review. J. Clin. Oncol. 2006, 24:1761-1769.
94. Lamberti C., et al. Arylamine N-acetyltransferase type 2 and glutathione S-transferases M1 and T1 polymorphisms in familial adenomatous polyposis. Pharmacogenetics 2002, 12:49-54.
95. Yang T.L., et al. Genome-wide copy-number-variation study identified a susceptibility gene, UGT2B17, for osteoporosis. Am. J. Hum. Genet. 2008, 83:663-674.